Vapotherm, Inc.

Vapotherm manufactures high-velocity therapy (HVT) respiratory support systems for spontaneously breathing patients across neonatal, pediatric, and adult care settings. The company's proprietary mask-free approach delivers heated, humidified high-flow nasal therapy as an alternative to noninvasive positive pressure ventilation (NiPPV) and continuous positive airway pressure (nCPAP), addressing patient compliance challenges due to mask intolerance from anxiety, injury, or other factors. Primary product lines include the HVT 2.0 System (pediatrics to adults) and Precision Flow Hi-VNI (neonates). Clinical evidence supports efficacy in preventing intubation for spontaneously breathing patients, including premature infants in NICUs, pediatric populations, and adults with moderate to severe acute exacerbations in emergency and critical care settings. Vapotherm devices are restricted to physician order under US federal law and are available in more than 40 countries. The company serves over 2,400 hospitals globally and has delivered therapy to more than 4.1 million patients. Devices are designed for ease of use with simplified controls and real-time display of flow rate, temperature, and FiO2 concentration. Clinical documentation references randomized controlled trials demonstrating non-inferiority to standard NiPPV in preventing intubation across patient populations.